Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years of age or older
Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
Completed chemotherapy with no cardiotoxicity at least two years post treatment
Disqualifiers
None
Trial population
Patients who were treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Non-Interventional Study
Other interventionNon-interventional study
Treatment groups
693 Participants
are divided into 1 treatment groupGroup A: Observational1 intervention
Trial outcomes
Primary outcomes
1
Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT
Assessed by the number of participants who participate and consent to have their specimen (blood draw) retained for future research.
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Mayo Clinic
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov